CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Operating expenses
Cost of product revenue	$ 2,333,000	$ 3,280,000
Research and development	15,079,000	6,413,000
Sales and marketing	8,894,000	6,609,000
General and administrative	17,103,000	14,387,000
Series 3 warrants inducement expense	1,462,000	3,696,000
ELOC warrants inducement expense	172,000
Series B convertible preferred stock inducement expense		1,647,000
Total operating expenses	45,043,000	36,032,000
Loss from operations	(40,708,000)	(26,647,000)
Interest expense	(8,421,000)	(2,792,000)
Loss on extinguishment of debt and exchange of Series D perpetual preferred stock	(753,000)	(1,864,000)
Change in fair value of financial instruments and hybrid instrument designated at Fair Value Option	(1,953,000)	(2,696,000)
Other income (expense), net	(765,000)	190,000
Loss before income tax	(52,600,000)	(33,809,000)
Income tax expense	0	0
Net loss and comprehensive loss	(52,600,000)	(33,809,000)
Adjusted net loss and comprehensive loss	(52,600,000)	(38,648,000)
Net loss attributable to noncontrolling interest	(5,000)
Net loss attributable to Common Stockholders, Basic	(52,595,000)	(38,648,000)
Net loss attributable to common shareholders, diluted	$ (52,595,000)	$ (38,648,000)
Net loss per share, basic	$ (1.18)	$ (3.00)
Net loss per share, diluted	$ (1.18)	$ (3.00)
Weighted-average common shares outstanding, basic	44,711,588	12,880,868
Weighted-average common shares outstanding, Diluted	44,711,588	12,880,868
Series C Perpetual Preferred Stock
Operating expenses
Deemed dividend		$ (2,521,000)
Stock dividend attributable to Series C perpetual preferred stock		(130,000)
Series A convertible preferred stock
Operating expenses
Deemed dividend		(1,332,000)
Series 1, Series 2 and Bridge warrant
Operating expenses
Deemed dividend		(856,000)
Product revenue, net
Revenue
Total revenue	$ 4,335,000	$ 9,385,000